Mice lacking ILC3-specific MHC II were found to develop invasive CRC and resist anti-PD-1 immunotherapy response, which may be associated with the collaboration of increased Th17 cell response and impaired type 1 immunity, implying that MHC II+ ILC3 played a protective role in CRC (126). This evidence concerns the gene PDCD1 and colorectal carcinoma.